[BRAF inhibitors-induced paradoxical reactions and oncogenesis]

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Targeted cancer therapies, such as small-molecule kinase inhibitors, can lead to unexpected side effects.
• Paradoxical oncogenesis and benign proliferations are observed in rapidly regenerating tissues off-target from these therapies.
• Patients with BRAF-mutated solid tumors treated with selective BRAF inhibitors are particularly susceptible.

Purpose of the Study:

• To investigate the phenomenon of paradoxical proliferations in off-target tissues during targeted cancer therapy.
• To understand the impact of combination therapies on reducing these adverse events.
• To explore the molecular complexity underlying paradoxical tissue growth.

Main Methods:

• Review of clinical data and literature on patients treated with small-molecule inhibitors.
• Analysis of incidence rates of paradoxical proliferations before and after the introduction of combination therapies.
• Comparative analysis of molecular mechanisms in off-target tissues versus malignant cells.

Main Results:

• Paradoxical proliferations were frequently observed in off-target tissues of patients receiving kinase inhibitors.
• The incidence of these proliferations decreased significantly with the adoption of BRAF/MEK double blockade therapies.
• The molecular underpinnings of these off-target effects appear highly complex.

Conclusions:

• Paradoxical oncogenesis is a recognized risk associated with targeted cell-signaling inhibitors.
• BRAF/MEK double blockade therapy effectively mitigates paradoxical proliferations in specific patient populations.
• Further research into the complex molecular pathways is warranted to fully elucidate these phenomena.